Welcome to the New Mexico Chapter of the American College of Cardiology
ACC Live Courses For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings |
Please join your cardiology colleagues at the ACC Rockies Chapter Meeting in Park City, Utah for updates on ACC affairs, the potential new CV Board, and clinical topics such as Genetic and Sports EP, plus a discussion on the growing role of obesity medications in heart failure, and the first-ever Cardiology State-of-the-State report. There will be many opportunities for networking, as well!.
For more information and to register, please visit: 
Latest in Cardiology from ACC.org
- The Relationship Between Exercise and Longevity: Challenging the U-Shaped HypothesisBased on epidemiologic studies, it has been posited that there is a U- or reverse J-shaped relationship between exercise and cardiovascular outcomes. The benefits of regular exercise on longevity are well described...
- New ACC Guidance Addresses Obesity Treatment Strategies Across the CV SpectrumAs obesity continues to drive cardiovascular risk, the ACC has released two new guidance documents to support clinicians: Concise Clinical Guidance (CCG) on the medical management of obesity and a Scientific Statement focused on treating obesity in adults with heart failure.
- Management of Recurrent Coarctation in ChildrenCoarctation of the aorta accounts for 5-8% of all congenital heart disease, with an incidence of approximately four cases per 10,000 live births. It can be seen in isolation or associated with other cardiac lesions.
- Oral, Subcutaneous Amycretin Similarly Safe, Tolerated as GLP-1 MonoagonistsAmycretin, a novel, unimolecular GLP-1 and amylin receptor agonist has a safety and tolerability profile similar with other GLP-1 and amylin agonists in both oral and subcutaneous formulations, according to two studies published in The Lancet.
- CAPLA: Long-Term QOL Improvement With CA For Persistent AFibQuality of life (QOL) at three years significantly improved following catheter ablation (CA) for persistent atrial fibrillation (PsAFib), according to a secondary analysis of patients in the CAPLA clinical trial published in JACC: Clinical Electrophysiology.